沙库巴曲缬沙坦治疗舒张性心衰患者疗效及对血清B型利钠肽的影响  

The efficacy of Sacubitril Valsartan in the treatment of patients with diastolic heart failure and its effect on serum B-type natriuretic peptide

作　　者：刘聪 Liu Cong(Department of Cardiology,Second People's Hospital of Wuqing District,Tianjin 301799,China)

机构地区：[1]天津市武清区第二人民医院,天津301799

出　　处：《首都食品与医药》2024年第6期64-67,共4页Capital Food Medicine

摘　　要：目的探讨沙库巴曲缬沙坦对舒张性心力衰竭(DHF)患者血清B型利钠肽及左室舒张功能的影响.方法回顾性分析天津市武清区第二人民医院收治的62例舒张性心衰患者资料,并分为对照组及治疗组,两组患者根据病情均给予心衰的基础治疗,治疗组同时加用沙库巴曲缬沙坦50mg BID(根据血压水平增减药物),观察治疗3个月.分别测定患者治疗前和治疗3个月后的BNP、左室舒张功能指标并比较有无差异.结果治疗后对照组LVEDD显著缩小(P<0.05);治疗组LVEDD、LAD、IVSD显著缩小(P<0.05),E/A显著增加(P<0.05).治疗组患者LAD小于对照组,E/A显著大于对照组(P<0.05);较之治疗前,对照组及治疗组治疗后BNP水平显著下降(P<0.05),且治疗组的BNP水平明显低于同期对照组(P<0.05).对照组和治疗组治疗3个月后有效率分别为67.7%(21/31)和87.1%(27/31),治疗组显著高于对照组(P<0.05).治疗后有效患者48例,无效患者14例,无效患者血清BNP为(160.01±16.34)ng/L,显著高于有效患者的(130.80±21.10)ng/L,且有统计差异(P<0.05).以血清BNP作为疗效评价预测指标,其预测有效率的敏感性为76.87%,特异性为81.23%,ROC曲线下面积为0.81(95%CI:0.70-0.91).结论沙库巴曲缬沙坦能够降低舒张性心衰患者BNP水平,能逆转左室重塑、改善舒张功能效应,并可将BNP作为疗效评估的预测指标.Objective To investigate the effects of Sacubitril Valsartan on serum B-type natriuretic peptide and left ventricular diastolic function in patients with diastolic heart failure(HDF).Method A retrospective analysis was conducted on 62 patients with diastolic heart failure admitted to the Second People's Hospital of Wuqing District,Tianjin,and they were divided into a control group and a treatment group.Both groups of patients received basic treatment for heart failure based on their condition.The treatment group also received Sacubitril Valsartan 50mg BID(based on blood pressure levels),and the treatment was observed for 3 months.Measure the BNP and left ventricular diastolic function indicators of patients before enrollment and after 3 months of treatment,and compare for any differences.Result After treatment,the LVEDD of the control group significantly decreased(P<0.05);the LVEDD,LAD,and IVSD in the treatment group were significantly reduced(P<0.05),while E/A was significantly increased(P<0.05).The LAD of patients in the treatment group was lower than that in the control group,and the E/A was significantly higher than that in the control group(P<0.05);compared to before treatment,the BNP levels in the control group and the treatment group decreased significantly after treatment(P<0.05),while the BNP levels in the treatment group were significantly lower than those in the control group during the same period(P<0.05).The effective rates in the control group and the treatment group were 67.7%(21/31)and 87.1%(27/31),respectively.The treatment group was significantly higher than the control group(P<0.05).After treatment,there were 48 effective patients and 14 ineffective patients.The serum BNP of ineffective patients was(160.01±16.34)ng/L,significantly higher than that of the effective patients(130.80±21.10)ng/L,and there was a statistical difference(P<0.05).Serum BNP serves as a reference for efficacy evaluation,with a sensitivity of 76.87%and specificity of 81.23%for predicting effective rate.The area under the

关 键 词：舒张性心衰 沙库巴曲缬沙坦 B型利钠肽(BNP) 

分 类 号：R541.6[医药卫生—心血管疾病]